The success of BEAM-301 marks the first clinical proof that in vivo base editing can address the root cause of a rare inherited liver disease.
First clinical proof of base editing in the human liver
Mechanism of nanoparticle action and doubling of safe fasting hours
Sharp decline in patients’ daily cornstarch requirements
Medical safety profile and upcoming regulatory steps with the FDA
Frequently asked questions
First clinical proof of base editing in the human liver
Beam Therapeutics announced on Tuesday, October 13, 2026, that its experimental base editing treatment known as BEAM-301 has successfully restored the body’s native ability to produce glucose in early patients with glycogen storage disease type Ia. The company intends to present preliminary phase 1/2 clinical trial results at the European Society of Gene and Cell Therapy congress, held from October 27 to 30 in Hamburg, Germany.
These data come from 6 patients participating in the study. Although medical follow-up for the highest dose group remains short, the findings represent the world’s first clinical evidence proving that a base editing tool designed to repair a specific patient mutation can address the root cause of this rare liver disorder.
Beam described the results as a “clinical proof of concept,” with specialized publication Endpoints News publishing details of the results on the same day.
Mechanism of nanoparticle action and doubling of safe fasting hours
BEAM-301 is administered to patients as a one-time intravenous infusion, utilizing lipid nanoparticles to carry base editing machinery and deliver it directly to liver cells to correct a genetic mutation known as R83C. This mutation is one of the most common causes of glycogen storage disease type Ia and is associated with its most severe forms, as affected patients typically require frequent doses of raw cornstarch, including overnight, and can enter life-threatening hypoglycemic shock within 1 to 3 hours if a dose is missed.
As of the data cutoff date of June 26, 3 patients had received a 20-milligram dose and 3 had received a 40-milligram dose, with efficacy unassessable in one patient in the 40-milligram cohort due to recent treatment.
In the 20-milligram cohort, the mean time to hypoglycemia during fasting increased from 2.9 hours pre-treatment to 4.3 hours by day 36, while both evaluable patients in the 40-milligram cohort reached the trial’s maximum monitored fasting limit of at least 15 hours, up from a baseline group average of just 2.5 hours.
Sharp decline in patients’ daily cornstarch requirements
The improvement in natural hepatic glucose production translated directly into reduced patient reliance on dietary supplements, with medically prescribed daily cornstarch consumption falling by 71 percent and 92 percent in the two patients within the 40-milligram cohort.
In the 20-milligram dose group, daily starch consumption decreased by 74 percent, 71 percent, and 11 percent across the three patients, noting that the average follow-up period was 313 days in the 20-milligram group compared to just 53 days in the 40-milligram group.
Dr. Amy Simon, chief medical officer at Beam, stated: “Most notably, evaluable patients in the 40-milligram dose cohort achieved 15 hours or more of monitored fasting and saw substantial, major reductions in starch intake requirements.”
Medical safety profile and upcoming regulatory steps with the FDA
The company described the treatment’s safety profile as acceptable and consistent with other lipid nanoparticle-based therapies. Every patient experienced at least one treatment-related adverse event, with 5 serious adverse events recorded including 3 grade 3 infusion-related reactions, all of which resolved and recovered within 2 to 10 days. Beam explained that short-acting steroids received by patients prior to infusion may have contributed to these reactions, and the company has since modified the steroid protocol, emphasizing that no dose-limiting toxicities, deaths, or discontinuations occurred.
Investigator Rebecca Riba-Wolman from Connecticut Children’s Medical Center will present updated results during a scientific poster session on October 28, while the company will host an investor webcast on October 27 at 8:00 AM Eastern Time.
The company previously stated it hopes to discuss potential regulatory flexibility with the US Food and Drug Administration, given that this rare disease affects at most a few hundred patients in the United States according to CEO John Evans.
Frequently asked questions
Question: How does the experimental gene therapy BEAM-301 work inside the body?
Answer: The treatment is administered once intravenously and uses lipid nanoparticles to deliver a base editing tool to the liver to correct the R83C mutation responsible for the disease.
Question: What are the standout results achieved by patients in the higher 40-milligram dose cohort?
Answer: Patients were able to undergo monitored fasting for at least 15 hours compared to about 2.5 hours before treatment, and their daily cornstarch requirements dropped by 71 percent and 92 percent.
Question: Did any serious side effects appear during the clinical trial?
Answer: Five serious adverse events were recorded including 3 infusion reactions, but all resolved within 2 to 10 days. The company adjusted the pre-steroid regimen, and no deaths were reported.
Question: When and where will detailed results of this clinical study be presented?
Answer: Results will be presented at the European Society of Gene and Cell Therapy congress in Hamburg, Germany, between October 27 and 30, 2026.